Who owns FDMT?
Institutional ownership of 4D Molecular Therapeutics Inc. from Form 13F, Q2 2026
158 institutional managers reported holding 4D Molecular Therapeutics Inc. (FDMT) in Form 13F filings for Q2 2026, with 58,110,345 shares worth $772M. The largest reported holder was Jupiter Topco LLC. Managers that filed both quarters added a net 6,994,699 shares (+15.4%). 29 opened new positions and 23 sold out.
- Funds holding
- 158
- Value held
- $772M
- New / sold out
- 29 / 23
- Net shares, same filers
- +15.4%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of FDMT
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Jupiter Topco LLC | $76.5M | 9.9% | 5,746,289 | First report |
| Ra Capital Management, L.p. | $67.2M | 8.7% | 5,049,779 | Unchanged |
| BlackRock, Inc. | $60.5M | 7.8% | 4,546,059 | Added |
| Goldman Sachs Group Inc | $56.6M | 7.3% | 4,258,668 | Added |
| Novo Holdings A/S | $43.2M | 5.6% | 3,249,178 | Trimmed |
| State Street Corp | $38.7M | 5.0% | 2,911,109 | Added |
| BVF Inc | $38.3M | 5.0% | 2,879,289 | Unchanged |
| T. Rowe Price Investment Management, Inc. | $33.4M | 4.3% | 2,511,887 | New |
| Adage Capital Partners GP, L.l.c. | $29.9M | 3.9% | 2,249,203 | Added |
| Trails Edge Capital Partners, LP | $29.6M | 3.8% | 2,227,917 | Added |
| Vanguard Capital Management LLC | $27.9M | 3.6% | 2,099,055 | Trimmed |
| Armistice Capital, LLC | $26.6M | 3.4% | 2,000,000 | Unchanged |
| Geode Capital Management, LLC | $15.0M | 1.9% | 1,128,466 | Added |
| Bank of America Corp | $14.9M | 1.9% | 1,120,674 | Added |
| Evergreen Quality Fund GP, Ltd. | $12.7M | 1.6% | 951,474 | Unchanged |
| Parkman Healthcare Partners LLC | $12.6M | 1.6% | 948,184 | Added |
| Dimensional Fund Advisors LP | $9.7M | 1.3% | 730,857 | Added |
| Deutsche Bank Ag\ | $9.5M | 1.2% | 710,942 | Added |
| Citadel Advisors LLC | $9.1M | 1.2% | 687,597 | Added |
| Renaissance Technologies LLC | $8.2M | 1.1% | 614,573 | Added |
| Vanguard Portfolio Management LLC | $7.7M | 1.0% | 579,903 | Added |
| Diadema Partners LP | $7.6M | 1.0% | 571,107 | New |
| Northern Trust Corp | $7.5M | 1.0% | 562,929 | Added |
| Acuta Capital Partners, LLC | $6.8M | 0.9% | 507,801 | New |
| Nuveen, LLC | $6.7M | 0.9% | 503,071 | Trimmed |
Share of 13F holdings is each fund's shares as a share of the 58,110,345 FDMT shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- T. Rowe Price Investment Management, Inc. New+$33.4M
- Trails Edge Capital Partners, LP Added+$12.3M
- Adage Capital Partners GP, L.l.c. Added+$8.6M
- Diadema Partners LP New+$7.6M
- Acuta Capital Partners, LLC New+$6.8M
- Catalio Capital Management, LP New+$6.3M
- Parkman Healthcare Partners LLC Added+$5.7M
- Citadel Advisors LLC Added+$5.6M
- BlackRock, Inc. Added+$5.3M
- Schonfeld Strategic Advisors LLC Added+$4.1M
Biggest sellers in Q2 2026
- Federated Hermes, Inc. Trimmed-$16.1M
- Novo Holdings A/S Trimmed-$5.3M
- Peapod Lane Capital LLC Sold out-$2.2M
- Invesco Ltd. Trimmed-$2.1M
- Propel Bio Management, LLC Trimmed-$1.7M
- Susquehanna International Group, LLP Trimmed-$1.5M
- Vanguard Capital Management LLC Trimmed-$1.3M
- Exome Asset Management LLC Sold out-$1.2M
- ADAR1 Capital Management, LLC Sold out-$1.1M
- Privium Fund Management B.V. Trimmed-$1.1M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $137M and sold $41.0M; 63 added and 35 trimmed.
Schedule 13D and 13G filings on FDMT
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.Schedule 13G
- 2026-05-12STATE STREET CORP SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.Schedule 13G
- 2026-02-17JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.Schedule 13G
- 2025-10-20Novo Holdings A/S SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.Schedule 13G
Questions about FDMT ownership
- Who owns FDMT stock?
- 158 institutional investment managers reported FDMT positions in their Form 13F filings for Q2 2026, holding 58,110,345 shares worth $772M in total. Jupiter Topco LLC reported the largest position.
- Are funds buying or selling FDMT?
- In Q2 2026, 29 managers opened new FDMT positions, 63 added, 35 trimmed and 23 sold out. Managers that filed in both quarters added a net 6,994,699 shares.
- How current is this FDMT institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to FDMT by CUSIP. Options are left out. FDMT news and filings · FDMT insider trades · Top funds